Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary Sclerosing Cholangitis (PSC)
- Main trialPhase 2
- “The cause of PSC is unknown.To date, there is no treatment besides liver transplantation proven to improve PSC prognosis. However, there is a clear medical unmet need yet for patients with PSC, due to risks and complications of liver transplantation. This is a two-part, Phase 2b, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of HK-660S in patients with PSC. The primary objective is to evaluate the effects of HK-660S on serum ALP improvement (reduction of 20% or more) over 12 weeks of treatment in patients with PSC.”In the company’s words, NCT06975150 on ClinicalTrials.gov
Other drugs for Primary Sclerosing Cholangitis (PSC)
- Norucholic acidDr. Falk Pharma GmbH · Phase 3
- ElafibranorIpsen · Phase 3
- MaralixibatMirum Pharmaceuticals, Inc. · Phase 3
- LB-P8LISCure Biosciences · Phase 2
- VolixibatMirum Pharmaceuticals, Inc. · Phase 2
- TAK-781Takeda · Phase 1
Coming up1
- 30 Aug 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 30 Aug 2028 | Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis | |
| Phase 2Completed | 23 Jun 2023 | Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026